Daniel Loeb
Third Point
Daniel Loeb HORIZON THERAPEUTICS PLC stake
total: 588
Third Point HZNP trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2023 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q3
According to 2026 Q2 report, Daniel Loeb doesn't hold any HORIZON THERAPEUTICS PLC (HZNP) shares. To date, the estimated cost basis is nearly $102.85 for "buy" trades and estimated average "sell" price is $102.85. Third Point first purchased HZNP in 2023 Q2, initially acquiring 500,000 shares. Since the initial investment in HORIZON THERAPEUTICS PLC (HZNP), Third Point has made 1 more transaction.
When did Daniel Loeb sell HORIZON THERAPEUTICS PLC (HZNP)?
Daniel Loeb sold off the entire HORIZON THERAPEUTICS PLC (HZNP) position in 2023 Q3.
When did Daniel Loeb buy HORIZON THERAPEUTICS PLC (HZNP)?
Daniel Loeb first invested in HORIZON THERAPEUTICS PLC (HZNP) in 2023 Q2 at the reported quarter-end price of $102.85 per share.
What's the cost basis of Third Point's HZNP stake?
The estimated cost basis for HORIZON THERAPEUTICS PLC (HZNP) stake is around $102.85 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $102.85
- Weighted AVG sell price:
- $102.85
Daniel Loeb's historical trades in HORIZON THERAPEUTICS PLC
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$102.85
|
|
-100% (-500,000)
|
-0.75%
|
|
2023 Q2
|
0.75%
|
500,000
|
$102.85
|
$51,425,000
|
new
|
+0.75%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.